Skip to main content

Adda Nathalie's Form 4 filing

Enanta Pharmaceuticals Inc (ENTA) · filed Mar 3, 2022

Accession no.
0001062993-22-006708
Filed
Mar 3, 2022
Trade date
Mar 1-2, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.58M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Adda NathalieCIK 0001646976Officer (Sr. VP & Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 1, 2022Common StockMOption exerciseAcquired+24,339$43.46+$1,057,772.9459,321Direct
Mar 1, 2022Common StockSSaleDisposed−24,239$70.26−$1,703,032.1435,082Direct
Mar 1, 2022Common StockSSaleDisposed−100$71.06−$7,10634,982Direct
Mar 2, 2022Common StockMOption exerciseAcquired+12,481$43.46+$542,424.2647,463Direct
Mar 2, 2022Common StockSSaleDisposed−12,481$70.07−$874,543.6734,982Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 1, 2022Common StockMOption exerciseDisposed−24,339$0.00$012,481Direct
Mar 2, 2022Common StockMOption exerciseDisposed−12,481$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)